NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen with Roche’s MabThera. The cost-effectiveness agency ...

Bristol-Myers Squibb's blood cancer blockbuster Revlimid is finally facing generic competition in the US, which will eat into revenues from a drug that made a massive $12.8 billion in sales last year.